|
1
|
Villanueva MT: Combination therapy: update
on gastric cancer in East Asia. Nat Rev Clin Oncol. 8:6902011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leung WK, Wu MS, Kakugawa Y, et al:
Screening for gastric cancer in Asia: current evidence and
practice. Lancet Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Widschwendter M and Jones PA: DNA
methylation and breast carcinogenesis. Oncogene. 21:5462–5482.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schoof CR, Botelho EL, Izzotti A and dos
Vasques LR: MicroRNAs in cancer treatment and prognosis. Am J
Cancer Res. 2:414–433. 2012.PubMed/NCBI
|
|
5
|
Hu J, Cheng Y, Li Y, et al: microRNA-128
plays a critical role in human non-small cell lung cancer
tumourigenesis, angiogenesis and lymphangiogenesis by directly
targeting vascular endothelial growth factor-C. Eur J Cancer.
50:2336–2350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakata K, Ohuchida K, Mizumoto K, et al:
MicroRNA-10b is overexpressed in pancreatic cancer, promotes its
invasiveness, and correlates with a poor prognosis. Surgery.
150:916–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishida N, Yamashita S, Mimori K, et al:
MicroRNA-10b is a prognostic indicator in colorectal cancer and
confers resistance to the chemotherapeutic agent 5-fluorouracil in
colorectal cancer cells. Ann Surg Oncol. 19:3065–3071. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu K, Li G, Fan C, Zhou X, Wu B and Li J:
Increased expression of microRNA-21and its association with
chemotherapeutic response in human colorectal cancer. J Int Med
Res. 39:2288–2295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang L, Mao P, Song L, et al: miR-182 as
a prognostic marker for glioma progression and patient survival. Am
J Pathol. 177:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adachi R, Horiuchi S, Sakurazawa Y,
Hasegawa T, Sato K and Sakamaki T: ErbB2 down-regulates
microRNA-205 in breast cancer. Biochem Biophys Res Commun.
411:804–808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chao A, Lin CY, Lee YS, et al: Regulation
of ovarian cancer progression by microRNA-187 through targeting
Disabled homolog-2. Oncogene. 31:764–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chai H, Liu M, Tian R, Li X and Tang H:
miR-20a targets BNIP2 and contributes chemotherapeutic resistance
in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta
Biochim Biophys Sin (Shanghai). 43:217–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gocek E, Wang X, Liu X, Liu CG and
Studzinski GP: MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3
in human myeloid leukemia cells leads to Bim targeting and
inhibition of AraC-induced apoptosis. Cancer Res. 71:6230–6239.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kovalchuk O, Filkowski J, Meservy J, et
al: Involvement of microRNA-451 in resistance of the MCF-7 breast
cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther.
7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen J, Tian W, Cai H, He H and Deng Y:
Down-regulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Li Z, Gao C, et al: miR-21 plays
a pivotal role in gastric cancer pathogenesis and progression. Lab
Invest. 88:1358–1366. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan SH, Wu CW, Li AF, Chi CW and Lin WC:
miR-21 microRNA expression in human gastric carcinomas and its
clinical association. Anticancer Res. 28:907–911. 2008.PubMed/NCBI
|
|
18
|
Lai KW, Koh KX, Loh M, et al:
MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric
cancer. Eur J Cancer. 46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Zhu W, Zhang J, et al:
MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity.
Biochem Biophys Res Commun. 395:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu Q, Jin H, Yang Z, et al: MiR-150
promotes gastric cancer proliferation by negatively regulating the
pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 392:340–345.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang Z, Guo J, Xiao B, et al: Increased
expression of miR-421 in human gastric carcinoma and its clinical
association. J Gastroenterol. 45:17–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao B, Guo J, Miao Y, et al: Detection of
miR-106a in gastric carcinoma and its clinical significance. Clin
Chim Acta. 400:97–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia L, Zhang D, Du R, et al: miR-15b and
miR-16 modulate multidrug resistance by targeting BCL2 in human
gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu W, Zhu D, Lu S, et al: miR-497
modulates multidrug resistance of human cancer cell lines by
targeting BCL2. Med Oncol. 29:384–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Orso F, Penna E, Cimino D, et al:
AP-2alpha and AP-2gamma regulate tumor progression via specific
genetic programs. FASEB J. 22:2702–2714. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jonckheere N, Fauquette V, Stechly L, et
al: Tumour growth and resistance to gemcitabine of pancreatic
cancer cells are decreased by AP-2alpha overexpression. Br J
Cancer. 101:637–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allouche A, Nolens G, Tancredi A, et al:
The combined immunodetection of AP-2alpha and YY1 transcription
factors is associated with ERBB2 gene overexpression in primary
breast tumors. Breast Cancer Res. 10:R92008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thorsen J, Aamot HV, Roberto R, Tjonnfjord
GE, Micci F and Heim S: Myelodysplastic syndrome with a
t(2;11)(p21;q23–24) and translocation breakpoint close to
miR-125b-1. Cancer Genet. 205:528–532. 2012.
|
|
29
|
Liu J, Chen G, Feng L, et al: Loss of p53
and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from
TCL1-Tg:p53(−/−) mouse model and primary human leukemia cells.
Leukemia. 28:118–128. 2014.PubMed/NCBI
|
|
30
|
Kent OA, Chivukula RR, Mullendore M, et
al: Repression of the miR-143/145 cluster by oncogenic Ras
initiates a tumor-promoting feed-forward pathway. Genes Dev.
24:2754–2759. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hertel J, Bartschat S, Wintsche A, Otto C
and Stadler PF: Evolution of the let-7 microRNA family. RNA Biol.
9:231–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wickramasinghe NS, Manavalan TT, Dougherty
SM, Riggs KA, Li Y and Klinge CM: Estradiol downregulates miR-21
expression and increases miR-21 target gene expression in MCF-7
breast cancer cells. Nucleic Acids Res. 37:2584–2595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jones K, Nourse JP, Keane C, Bhatnagar A
and Gandhi MK: Plasma microRNA are disease response biomarkers in
classical Hodgkin lymphoma. Clin Cancer Res. 20:253–264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blower PE, Verducci JS, Lin S, et al:
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol
Cancer Ther. 6:1483–1491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Salter KH, Acharya CR, Walters KS, et al:
An integrated approach to the prediction of chemotherapeutic
response in patients with breast cancer. PLoS One. 3:e19082008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bertino JR, Banerjee D and Mishra PJ:
Pharmacogenomics of microRNA: a miRSNP towards individualized
therapy. Pharmacogenomics. 8:1625–1627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meng F, Henson R, Lang M, et al:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bussing I, Slack FJ and Grosshans H: let-7
microRNAs in development, stem cells and cancer. Trends Mol Med.
14:400–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsang WP and Kwok TT: Let-7a microRNA
suppresses therapeutics-induced cancer cell death by targeting
caspase-3. Apoptosis. 13:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang H, Kong W, He L, et al: MicroRNA
expression profiling in human ovarian cancer: miR-214 induces cell
survival and cisplatin resistance by targeting PTEN. Cancer Res.
68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu M, Chen X, Chen N, et al: Synergistic
silencing by promoter methylation and reduced AP-2α transactivation
of the proapoptotic HRK gene confers apoptosis resistance and
enhanced tumor growth. Am J Pathol. 182:84–95. 2013.PubMed/NCBI
|
|
43
|
Fu L, Chen W, Guo W, et al: Berberine
Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and
Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell
Growth. PLoS One. 8:e692402013.PubMed/NCBI
|
